Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.50 |
| ▸ | CA1 | P00915 | 14/20 | 0.50 |
| ▸ | CA9 | Q16790 | 14/20 | 0.50 |
| ▸ | CA7 | P43166 | 11/20 | 0.50 |
| ▸ | CA4 | P22748 | 9/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7771595 | 1.00 | CA2 (0.50) | CA2CA1CA9CA7CA4 | |
| SCHEMBL7774542 | 0.91 | CA2 (0.43) | CA2CA1CA9CA7CA4 | |
| SCHEMBL7772401 | 0.89 | MEN1 (0.40) | CA2CA1CA9CA7CA4 | |
| SCHEMBL7771601 | 0.88 | ADRB2 (0.41) | CA2CA1CA9CA7CA4 | |
| SCHEMBL7771600 | 0.88 | ADRB2 (0.41) | CA2CA1CA9CA7CA4 | |
| SCHEMBL7771953 | 0.87 | CA2 (0.44) | CA2CA1CA9CA7CA4 | |
| SCHEMBL7771955 | 0.87 | CA2 (0.44) | CA2CA1CA9CA7CA4 | |
| Hydrochloric Acid SCHEMBL7772036 | 0.86 | CA2 (0.44) | CA2CA1CA9CA7CA4 | |
| Hydrochloric Acid SCHEMBL7772032 | 0.86 | CA2 (0.44) | CA2CA1CA9CA7CA4 | |
| SCHEMBL7769942 | 0.86 | MEN1 (0.39) | CA2CA1CA9CA7CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115706-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018730-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| US-7329401-B2 | Cyclooxygenase-2 selective agents useful as imaging probes and related methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070286801-A1 | CYCLOOXYGENASE-2 SELECTIVE AGENTS USEFUL AS IMAGING PROBES AND RELATED METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-13 | — | — | US | disclosed |
| WO-2003089013-A1 | CYCLOOXYGENASE-2 SELECTIVE AGENTS USEFUL AS IMAGING PROBES AND RELATED METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1115706-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018730-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070286801-A1 | CYCLOOXYGENASE-2 SELECTIVE AGENTS USEFUL AS IMAGING PROBES AND RELATED METHODS | PTGS2, PTGES2, PTGER2 | CA2 508/4885CA1 2417/4885CA9 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.